SYDNEY BYRD: Open Payments
NPI 1538924436 · GREENVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,210 in 131 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $1,109 · 2025 $2,210
Food & beverage: $2,210
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $339 |
| Otsuka America Pharmaceutical, Inc. | 21 | $330 |
| ABBVIE INC. | 28 | $305 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $177 |
| Lundbeck LLC | 8 | $170 |
| Axsome Therapeutics, Inc. | 8 | $146 |
| Alkermes, Inc. | 5 | $117 |
| Noven Therapeutics, LLC | 5 | $96 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Bausch Health US, LLC | 3 | $70 |
Products named: REXULTI, CAPLYTA, VRAYLAR, TRINTELLIX, Auvelity, Xelstrym, HETLIOZ, APLENZIN.
Industry payments across SC — which companies pay providers there.
